Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs

Abstract

The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-β-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid. The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-β-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid.

1 . Product containing at least one connexin-blocking agent and a psychotropic drug, as combination products for simultaneous, separate or sequential use over time, in patients with psychiatric and/or neurodegenerative disorders.  
     
     
         2 . Product according to  claim 1 , characterized in that the connexin-blocking agent is chosen from the group including meclofenamic acid, 18-β-glycyrrhetinic acid, mefloquine and 2-APB, and is preferably meclofenamic acid.  
     
     
         3 . Product according to claims  1  and  2 , characterized in that the psychotropic drug is a dopaminergic, GABAergic, adrenergic, acetylcholinergic, serotoninergic, opioidergic, adenosinergic, ionotropic, histaminergic, IMAO, Catechol-O-methyl transferase, DOPA decarboxylase or noradrenergic effector.  
     
     
         4 . Product according to  claim 3 , characterized in that the psychotropic drug is a dopaminergic effector chosen from loxapine, acepromazine, methylphenidate, amantadine, pergolide, lisuride, bromocriptine, ropinirole, apomorphine, aripiprazole, sulpiride, amisulpride, sultopride, tiapride, pimozide, risperidone, haloperidol, penfluridol, zuclopenthixol or bupropion.  
     
     
         5 . Product according to  claim 3 , characterized in that the psychotropic drug is a GABAergic effector chosen from tiagabine, topiramate, clorazepate, diazepam, clonazepam, oxazepam, lorazepam, bromazepam, lormetazepam, nitrazepam, clotiazepam, alprozolam, estazolam, triazolam, loprazolam, etifoxin, meprobamate, zopiclone, zolpidem, phenobarbital, felbamate or vigabatrine.  
     
     
         6 . Product according to  claim 3 , characterized in that the psychotropic drug is an adrenergic effector chosen from dihydroergotamine, modafinil, adrafinil, mirtazapine or oxetorone.  
     
     
         7 . Product according to  claim 3 , characterized in that the psychotropic drug is an acetylcholinergic effector chosen from sulbutiamine, tropatepin or trihexyphenidyl.  
     
     
         8 . Product according to  claim 3 , characterized in that the psychotropic drug is a serotoninergic effector chosen from chlorpromazine, trimipramine, clozapine, olanzapine, cyamemazine, flupentixol, nefopam, fluvoxamine, clomipramine, sertraline, fluoxetine, citalopram, escitalopram, paroxetine, amitriptyline, duloxetine, venlafaxine, buspirone, carpipramine, zolmitriptan, sumatriptan, naratriptan, indoramine, ergotamine, ergotamine tartrate, pizotifene, pipamperone, methysergide, pizotyline, tianeptine, milnacipran, trimipramine, viloxazine, tianeptine, hypericum and lithium.  
     
     
         9 . Product according to  claim 3 , characterized in that the psychotropic drug is an opioidergic effector chosen from nalbuphine, buprenorphine, pethidine, codeine, tramadol, morphine, hydromorphone, oxycodone, methadone, dextropropoxyphene, meperidine, fentanyl, naltrexone or morphine hydrochloride.  
     
     
         10 . Product according to  claim 3 , characterized in that the psychotropic drug is an adenosinergic effector chosen from carbamazepine or oxcarbazepine.  
     
     
         11 . Product according to  claim 3 , characterized in that the psychotropic drug is an ionotropic effector chosen from flunarizine, ethosuximide, levetiracetam, lamotrigine, fosphenytoin or phenyloin.  
     
     
         12 . Product according to  claim 3 , characterized in that the psychotropic drug is a histaminergic effector chosen from niaprazine, hydroxyzine or doxylamine.  
     
     
         13 . Product according to  claim 3 , characterized in that the psychotropic drug is a monoamine oxidase effector chosen from moclobemide, selegiline or iproniazid.  
     
     
         14 . Product according to  claim 3 , characterized in that the psychotropic drug is a catechol-O-methyl transferase effector chosen from entacapone or tolcapone.  
     
     
         15 . Product according to  claim 3 , characterized in that the psychotropic drug is a DOPA decarboxylase effector chosen from benserazide or carbidopa.  
     
     
         16 . Product according to  claim 3 , characterized in that the psychotropic drug is a noradrenergic effector such as mianserine, desipramine, moclobemide or bupropion.  
     
     
         17 . Product according to  claim 3 , characterized in that the psychotropic drug is an effector acting on the limbic system, such as gabapentin or captodiamine.  
     
     
         18 . Product according to  claim 3 , characterized in that the psychotropic drug is chosen from the group including clozapine, modafinil, paroxetine, diazepam, escitalopram, sertraline, venlafaxine and bupropion.  
     
     
         19 . Use of at least one connexin-blocking agent to prepare a drug intended to be administered before, simultaneously to or after a psychotropic drug, in particular as defined in one of  claims 1  to  18 , to treat a patient with psychiatric and/or neurodegenerative disorders.  
     
     
         20 . Use of at least one connexin-blocking agent according to  claim 19 , to potentiate the effect of a psychotropic drug in patients suffering from psychiatric and/or neurodegenerative disorders.  
     
     
         21 . Use of at least one connexin-blocking agent according to claims  19  or  20 , to reduce the doses of said psychotropic drug and/or to limit the adverse effects of said psychotropic drug, and/or to reduce the effects of failure and withdrawal.